{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T02:53:11Z","timestamp":1788576791447,"version":"build-2803163510"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T00:00:00Z","timestamp":1676332800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T00:00:00Z","timestamp":1676332800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Bayer"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The aim of this study was to describe features of disease activity in patients with treated stable macular neovascularisation (MNV) in neovascular age related macular degeneration (nAMD) using optical coherence tomography angiography (OCTA).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Thirty-two eyes of 32 patients with nAMD were included in this prospective, observational study. These patients were undergoing treatment with aflibercept on a treat-and-extend regimen attending an extension to a 12-week treatment interval.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>All subjects had no macular haemorrhage and no structural OCT markers of active MNV activity at the index 12-week treatment extension visit. 31\/32 OCTA images were gradeable without significant imaging artefact. The mean MNV size was 3.6mm<jats:sup>2<\/jats:sup>\u2009\u00b1\u20094.6mm<jats:sup>2<\/jats:sup> and 27 (87.1%) had detectable MNV blood flow. 29\/31 (93.5%) subjects had MNV with mature phenotypes including 10 non-specific, 10 tangle and 3 deadtree phenotypes. MNV halo and MNV central feeder vessel were noted in 18 (58.1%) and 19 (61.3%) of subjects respectively; only 1 (3.2%) subject was noted to have a MNV capillary fringe.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>MNV blood flow is still detectable using OCTA in the majority of subjects in this study with treated stable MNV. OCTA features associated included MNV mature phenotype, MNV feeder vessel, MNV halo and absence of capillary fringe.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12886-022-02749-5","type":"journal-article","created":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T00:03:37Z","timestamp":1676333017000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Biomarkers of macular neovascularisation activity using optical coherence tomography angiography in treated stable neovascular age related macular degeneration"],"prefix":"10.1186","volume":"23","author":[{"given":"Daren","family":"Hanumunthadu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azahir","family":"Saleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Florea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Balaskas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pearse A","family":"Keane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tariq","family":"Aslam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praveen J.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,14]]},"reference":[{"issue":"9","key":"2749_CR1","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1136\/bjophthalmol-2014-305702","volume":"98","author":"U Schmidt-Erfurth","year":"2014","unstructured":"Schmidt-Erfurth U, Chong V, Loewenstein A, Larsen M, Souied E, Schlingemann R, Eldem B, Mon\u00e9s J, Richard G, Bandello F. Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). Br J Ophthalmol. 2014;98(9):1144\u201367.","journal-title":"Br J Ophthalmol"},{"issue":"Suppl 1(Suppl 1","key":"2749_CR2","first-page":"1-s11","volume":"29","author":"M McKibbin","year":"2015","unstructured":"McKibbin M, Devonport H, Gale R, Gavin M, Lotery A, Mahmood S, Patel PJ, Ross A, Sivaprasad S, Talks J, et al. Aflibercept in wet AMD beyond the first year of treatment: recommendations by an expert roundtable panel. Eye (Lond). 2015;29(Suppl 1):1-s11.","journal-title":"Eye (Lond)"},{"issue":"7","key":"2749_CR3","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1111\/ceo.13837","volume":"48","author":"R Guymer","year":"2020","unstructured":"Guymer R, Wu Z. Age-related macular degeneration (AMD): More than meets the eye. The role of multimodal imaging in today's management of AMD-A review. Clin Exp Ophthalmol. 2020;48(7):983\u201395.","journal-title":"Clin Exp Ophthalmol"},{"key":"2749_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.preteyeres.2017.11.003","volume":"64","author":"RF Spaide","year":"2018","unstructured":"Spaide RF, Fujimoto JG, Waheed NK, Sadda SR, Staurenghi G. Optical coherence tomography angiography. Prog Retin Eye Res. 2018;64:1\u201355.","journal-title":"Prog Retin Eye Res"},{"issue":"35","key":"2749_CR5","doi-asserted-by":"publisher","first-page":"14354","DOI":"10.1073\/pnas.1307315110","volume":"110","author":"DY Kim","year":"2013","unstructured":"Kim DY, Fingler J, Zawadzki RJ, Park SS, Morse LS, Schwartz DM, Fraser SE, Werner JS. Optical imaging of the chorioretinal vasculature in the living human eye. Proc Natl Acad Sci U S A. 2013;110(35):14354\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"2749_CR6","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1097\/ICU.0000000000000469","volume":"29","author":"EW Schneider","year":"2018","unstructured":"Schneider EW, Fowler SC. Optical coherence tomography angiography in the management of age-related macular degeneration. Curr Opin Ophthalmol. 2018;29(3):217\u201325.","journal-title":"Curr Opin Ophthalmol"},{"issue":"9","key":"2749_CR7","doi-asserted-by":"publisher","first-page":"3690","DOI":"10.1167\/iovs.17-21941","volume":"58","author":"CM Eandi","year":"2017","unstructured":"Eandi CM, Ciardella A, Parravano M, Missiroli F, Alovisi C, Veronese C, Morara MC, Grossi M, Virgili G, Ricci F. Indocyanine Green Angiography and Optical Coherence Tomography Angiography of Choroidal Neovascularization in Age-Related Macular Degeneration. Invest Ophthalmol Vis Sci. 2017;58(9):3690\u20136.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"12","key":"2749_CR8","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1097\/IAE.0000000000001102","volume":"36","author":"MC Liang","year":"2016","unstructured":"Liang MC, de Carlo TE, Baumal CR, Reichel E, Waheed NK, Duker JS, Witkin AJ. Correlation of Spectral Domain Optical Coherence Tomography Angiography and Clinical Activity in Neovascular Age-Related Macular Degeneration. Retina. 2016;36(12):2265\u201373.","journal-title":"Retina"},{"key":"2749_CR9","doi-asserted-by":"publisher","first-page":"3751702","DOI":"10.1155\/2018\/3751702","volume":"2018","author":"A Miere","year":"2018","unstructured":"Miere A, Oubraham H, Amoroso F, Butori P, Astroz P, Semoun O, Bruyere E, Pedinielli A, Addou-Regnard M, Jung C, et al. Optical Coherence Tomography Angiography to Distinguish Changes of Choroidal Neovascularization after Anti-VEGF Therapy: Monthly Loading Dose versus Pro Re Nata Regimen. J Ophthalmol. 2018;2018:3751702.","journal-title":"J Ophthalmol"},{"issue":"11","key":"2749_CR10","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1097\/IAE.0000000000000836","volume":"35","author":"NW Muakkassa","year":"2015","unstructured":"Muakkassa NW, Chin AT, de Carlo T, Klein KA, Baumal CR, Witkin AJ, Duker JS, Waheed NK. Characterizing the Effect of Anti-Vascular Endothelial Growth Factor Therapy on Treatment-Naive Choroidal Neovascularization Using Optical Coherence Tomography Angiography. Retina. 2015;35(11):2252\u20139.","journal-title":"Retina"},{"issue":"9","key":"2749_CR11","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.oret.2018.01.014","volume":"2","author":"SM McClintic","year":"2018","unstructured":"McClintic SM, Gao S, Wang J, Hagag A, Lauer AK, Flaxel CJ, Bhavsar K, Hwang TS, Huang D, Jia Y, et al. Quantitative Evaluation of Choroidal Neovascularization under Pro Re Nata Anti-Vascular Endothelial Growth Factor Therapy with OCT Angiography. Ophthalmol Retina. 2018;2(9):931\u201341.","journal-title":"Ophthalmol Retina"},{"issue":"11","key":"2749_CR12","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1097\/IAE.0000000000000773","volume":"35","author":"A El Ameen","year":"2015","unstructured":"El Ameen A, Cohen SY, Semoun O, Miere A, Srour M, Quaranta-El Maftouhi M, Oubraham H, Blanco-Garavito R, Querques G, Souied EH. TYPE 2 NEOVASCULARIZATION SECONDARY TO AGE-RELATED MACULAR DEGENERATION IMAGED BY OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY. Retina. 2015;35(11):2212\u20138.","journal-title":"Retina"},{"issue":"2","key":"2749_CR13","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1097\/IAE.0000000000001628","volume":"38","author":"M Al-Sheikh","year":"2018","unstructured":"Al-Sheikh M, Iafe NA, Phasukkijwatana N, Sadda SR, Sarraf D. Biomarkers of Neovascular Activity in Age-Related Macular Degeneration Using Optical Coherence Tomography Angiography. Retina. 2018;38(2):220\u201330.","journal-title":"Retina"},{"issue":"9","key":"2749_CR14","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1136\/bjophthalmol-2018-313065","volume":"103","author":"F Coscas","year":"2019","unstructured":"Coscas F, Lupidi M, Boulet JF, Sellam A, Cabral D, Serra R, Francais C, Souied EH, Coscas G. Optical coherence tomography angiography in exudative age-related macular degeneration: a predictive model for treatment decisions. Br J Ophthalmol. 2019;103(9):1342\u20136.","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"2749_CR15","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1097\/IAE.0000000000001964","volume":"39","author":"A Miere","year":"2019","unstructured":"Miere A, Butori P, Cohen SY, Semoun O, Capuano V, Jung C, Souied EH. VASCULAR REMODELING OF CHOROIDAL NEOVASCULARIZATION AFTER ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY VISUALIZED ON OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY. Retina. 2019;39(3):548\u201357.","journal-title":"Retina"},{"key":"2749_CR16","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ajo.2017.12.005","volume":"187","author":"D Xu","year":"2018","unstructured":"Xu D, D\u00e1vila JP, Rahimi M, Rebhun CB, Alibhai AY, Waheed NK, Sarraf D. Long-term Progression of Type 1 Neovascularization in Age-related Macular Degeneration Using Optical Coherence Tomography Angiography. Am J Ophthalmol. 2018;187:10\u201320.","journal-title":"Am J Ophthalmol"},{"issue":"11","key":"2749_CR17","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1097\/IAE.0000000000000766","volume":"35","author":"GJ Coscas","year":"2015","unstructured":"Coscas GJ, Lupidi M, Coscas F, Cagini C, Souied EH. OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY VERSUS TRADITIONAL MULTIMODAL IMAGING IN ASSESSING THE ACTIVITY OF EXUDATIVE AGE-RELATED MACULAR DEGENERATION: A New Diagnostic Challenge. Retina. 2015;35(11):2219\u201328.","journal-title":"Retina"},{"issue":"4","key":"2749_CR18","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1111\/aos.13364","volume":"95","author":"F Sulzbacher","year":"2017","unstructured":"Sulzbacher F, Pollreisz A, Kaider A, Kickinger S, Sacu S, Schmidt-Erfurth U. Vienna Eye Study C: Identification and clinical role of choroidal neovascularization characteristics based on optical coherence tomography angiography. Acta Ophthalmol. 2017;95(4):414\u201320.","journal-title":"Acta Ophthalmol"},{"issue":"4","key":"2749_CR19","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1097\/IAE.0000000000001576","volume":"37","author":"Y Ichiyama","year":"2017","unstructured":"Ichiyama Y, Sawada T, Ito Y, Kakinoki M, Ohji M. Optical Coherence Tomography Angiography Reveals Blood Flow in Choroidal Neovascular Membrane in Remission Phase of Neovascular Age-Related Macular Degeneration. Retina. 2017;37(4):724\u201330.","journal-title":"Retina"},{"issue":"10","key":"2749_CR20","doi-asserted-by":"publisher","first-page":"e0205513","DOI":"10.1371\/journal.pone.0205513","volume":"13","author":"F Coscas","year":"2018","unstructured":"Coscas F, Cabral D, Pereira T, Geraldes C, Narotamo H, Miere A, Lupidi M, Sellam A, Papoila A, Coscas G, et al. Quantitative optical coherence tomography angiography biomarkers for neovascular age-related macular degeneration in remission. PLoS ONE. 2018;13(10):e0205513.","journal-title":"PLoS ONE"},{"issue":"11","key":"2749_CR21","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1097\/IAE.0000000000000879","volume":"35","author":"B Lumbroso","year":"2015","unstructured":"Lumbroso B, Rispoli M, Savastano MC. Longitudinal Optical Coherence Tomography-Angiography Study of Type 2 Naive Choroidal Neovascularization Early Response after Treatment. Retina. 2015;35(11):2242\u201351.","journal-title":"Retina"},{"issue":"2","key":"2749_CR22","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.canlet.2013.05.015","volume":"338","author":"S Bellou","year":"2013","unstructured":"Bellou S, Pentheroudakis G, Murphy C, Fotsis T. Anti-angiogenesis in cancer therapy: Hercules and hydra. Cancer Lett. 2013;338(2):219\u201328.","journal-title":"Cancer Lett"},{"issue":"4","key":"2749_CR23","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.ajo.2015.06.030","volume":"160","author":"L Kuehlewein","year":"2015","unstructured":"Kuehlewein L, Bansal M, Lenis TL, Iafe NA, Sadda SR, Bonini Filho MA, De Carlo TE, Waheed NK, Duker JS, Sarraf D. Optical Coherence Tomography Angiography of Type 1 Neovascularization in Age-Related Macular Degeneration. Am J Ophthalmol. 2015;160(4):739\u201348 e732.","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"2749_CR24","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1167\/iovs.17-23361","volume":"59","author":"PL Nesper","year":"2018","unstructured":"Nesper PL, Soetikno BT, Treister AD, Fawzi AA. Volume-Rendered Projection-Resolved OCT Angiography: 3D Lesion Complexity Is Associated With Therapy Response in Wet Age-Related Macular Degeneration. Invest Ophthalmol Vis Sci. 2018;59(5):1944\u201352.","journal-title":"Invest Ophthalmol Vis Sci"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-022-02749-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-022-02749-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-022-02749-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T00:04:04Z","timestamp":1676333044000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-022-02749-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,14]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2749"],"URL":"https:\/\/doi.org\/10.1186\/s12886-022-02749-5","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,14]]},"assertion":[{"value":"11 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study had ethics approval from Moorfields Eye Hospital Research Ethics Committee. All subjects gave informed consent prior to inclusion.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no relevant funding resources or competing interests. The views expressed in the publication are those of the authors and not necessarily those of the Department of Health.Dr Keane has acted as a consultant for DeepMind, Roche, Novartis, and Apellis and is an equity owner in Big Picture Medical. He has received speaker fees from Heidelberg Engineering, Topcon, Allergan, and Bayer. Dr Keane is supported by a Moorfields Eye Charity Career Development Award (R190028A) and a UK Research & Innovation Future Leaders Fellowship (MR\/T019050\/1).Dr Balaskas has received speaker fees from Novartis, Bayer, Alimera, Allergan and Heidelberg, consulting fees from Novartis and Roche and research support from Apellis, Roche, Novartis and Bayer.Dr Patel has received speaker fees from Novartis, Bayer, Topcon and Heidelberg, consulting fees from Novartis, Bayer, Oxford Bioelectronics and Roche and research support from Bayer.Professor Aslam has received speaker and consultancy fees from Novarits, Bayer, Roche, Topcon, Heidelberg, Alimera, Allergan, Canon, Thea.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"68"}}